HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Cancer vaccines targeted by many as the ‘holy grail’ for tumors
-
- Early death rate for APL remains high
- Ticagrelor: A review of the data leading to FDA approval Valerie Raney, PharmD; Zachary A. Stacy, PharmD, BCOP
- The role of HPV testing in patients with oropharynx cancer Barbara A. Burtness, MD
- Timing allogeneic transplant for CLL/SLL William Wood, MD
- Bosutinib a potential second-line treatment for chronic-phase CML
- ENESTnd: Nilotinib superior to imatinib for response, disease-specific death in chronic-phase CML at 2 years
- High rate of nurses exposed to chemotherapy drugs
- MERCURY: MRI predicted outcomes for locally advanced rectal cancer
-
- NSABP C-07: No evidence adjuvant oxaliplatin improved OS in colon cancer
- Targeting HPV 16/18 shows promise in cancer risk reduction
- Control rates similar after partial irradiation across various subtypes in early-stage breast cancer
- Locoregional outcomes unaffected by timing of chemotherapy
- Mammography continues to be beneficial in younger women
- Recurrence, survival rates similar for breast conservation, mastectomy in younger women
- Parental permission and the commitment to quality care Christine A. Zawistowski, MD
- Ipilimumab: Unleashing the power of T-cells in advanced melanoma Jaime E. Anderson, PharmD, BCOP; Laura Boehnke Michaud, PharmD
-